Free preview
LAQ Comprehensive
MD Pharmacology NMC syllabus Full notes Recent advances last updated on 2026-06-19

Antianginal Drugs

Pharmacotherapy of Ischemic Heart Disease — Nitrates, CCBs, β-blockers & Newer Agents

Past RGUHS + DNB + MPMSU + MUHS · 20 MPMSUOct '25 RGUHSJun '24 DNBOct '24 MUHSWinter '24 RGUHSDec '23 RGUHSJul '23 MPMSUJun '23 RGUHSNov '21 MPMSUMay '19 RGUHSNov '17 MPMSUJun '17 MPMSU2017 MUHSSummer '17 Suppl RGUHSNov '16 RGUHSJun '16 DNBDec '16 DNBDec '13 RGUHSOct '10 MPMSU2010 RGUHSMay '09

Antianginal Drugs

1. Definition & scope

  • Antianginal drugs are agents that prevent, abort or terminate attacks of angina pectoris (KDT 8e Ch.40, p.584).
  • Angina pectoris is chest pain (a heavy, pressing substernal discomfort, rather than true "pain") arising from accumulation of metabolites when there is an imbalance between myocardial O2 supply and O2 demand; the term literally means a "strangling feeling in the chest" (G&G 14e Ch.31, p.608; Katzung 16e Ch.12, p.200).
  • Typical pain radiates to the left shoulder, flexor aspect of the left arm, jaw or epigastrium; women, the elderly and diabetics more often present with atypical symptoms (G&G 14e Ch.31, p.608).
  • Ischemic heart disease (IHD) spans pathologies causing myocardial ischemia (reversible cell injury) through to myocardial infarction (irreversible necrosis) (G&G 14e Ch.31, p.607).
  • Myocardial ischemia may be silent — ECG/echo/radionuclide evidence without symptoms; β blockers are more effective than Ca2+ channel blockers at preventing silent ischemic episodes, but abolishing all silent ischemia confers no extra benefit over conventional therapy (G&G 14e Ch.31, pp.608–609).
Continue reading

Antianginal Drugs

PharmaNotes Pro · Comprehensive

Sign in with your Google account. If you're already subscribed, the chapter unlocks immediately — otherwise, pick Monthly or Annual on the next step.